Brief: Lupin Enters Settlement And License Agreement With Astellas
10/02/2026 02:18
Feb 10 (Reuters) - Lupin Ltd LUPN.NS: ENTERS SETTLEMENT AND LICENSE AGREEMENT WITH ASTELLAS TO PAY ASTELLAS $90 MILLION PREPAID PER UNIT LICENSE FEE FOR EACH UNIT SOLD FROM SETTLEMENT THROUGH SEPTEMBER 2027 Source text: ID:nNSE1RKHf2 Further company coverage: LUPN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)